Cellular Biomedicine Group Company Profile (NASDAQ:CBMG)

Analyst Ratings

Consensus Ratings for Cellular Biomedicine Group (NASDAQ:CBMG) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cellular Biomedicine Group (NASDAQ:CBMG)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cellular Biomedicine Group (NASDAQ:CBMG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/12/2016        
3/14/2016Q415($0.42)($0.43)$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q3($0.43)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2015Q215($0.37)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q115($0.40)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015($0.32)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/19/2014Q314($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cellular Biomedicine Group (NASDAQ:CBMG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellular Biomedicine Group (NASDAQ:CBMG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/22/2016Andrew K ChanSVPSell1,307$18.22$23,813.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Andrew K. ChanSVPSell1,516$17.76$26,924.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2016Andrew K. ChanSVPSell2,812$12.90$36,274.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Andrew K. ChanSVPSell12,812$21.94$281,095.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Andrew K. ChanSVPSell5,332$20.64$110,052.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Wei (William) CaoCEOSell20,000$19.59$391,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015Andrew K. ChanSVPSell5,215$20.20$105,343.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Andrew K. ChanSVPSell27,927$20.80$580,881.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Pak To LeungMajor ShareholderSell142,857$14.00$1,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014David BolocanDirectorBuy10,000$5.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Tony LiuCFOBuy100,000$5.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Keith WongDirectorSell320,050$0.13$41,606.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cellular Biomedicine Group (NASDAQ:CBMG)
DateHeadline
07/13/16 08:30 PMCellular Biomedicine : Announces Appointment of New Member to the Board of Directors
07/12/16 07:30 AMCellular Biomedicine Group Announces Appointment of New Member to the Board of Directors - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., July 12, 2016-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases ...
06/21/16 04:27 AM5:27 am Cellular Biomedicine to issue up to 5,137,905 shares of common stock for sale by selling shareholders -
06/17/16 04:08 PMETF’s with exposure to Cellular Biomedicine Group, Inc. : June 17, 2016 -
06/07/16 11:21 AMSystemic lupus erythematosus pipeline market review 2016 insights shared in detailed report
05/25/16 06:18 PMCELLULAR BIOMEDICINE GROUP, INC. : Shareholder Director Nominations (form 8-K) - 05/09 CELLULAR BIOMEDICINE: Reports First Quarter 2016 Financial Results and Provides.. 05/05 CELLULAR BIOMEDICINE GROUP, INC.: Change in Directors or Principal Officers (fo.. 04/20 CELLULAR BIOMEDICINE GROUP, INC.: Unregistered Sale of Equity Securities ...
05/25/16 10:02 AMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Shareholder Director Nominations -
05/24/16 10:18 AMBiotech Class Action Must Be Amended - The complaint cites these items, and other, from the blog post, referring to Cellular Biomedicine Group as CBMG. "With paid stock promotion CBMG has achieved an unsustainable $500m valuation, and with $20m in stock sold and insiders stock registered to ...
05/23/16 03:53 PMETF’s with exposure to Cellular Biomedicine Group, Inc. : May 23, 2016 -
05/23/16 12:25 PMCellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/19/16 09:49 AMMorning Biggest Movers – LTBR, ATRM, OSUR, SGYP, CBMG, CCXI, OHGI - Cellular Biomedicine Group Inc (CBMG) traded at $30.45 + 2.95 (10.73 pct) on 4,496 total stock volume. The company is +135.86 pct year-to-date, and +432.98 pct during the past four quarters. ChemoCentryx Inc. (CCXI) traded at $7.95 + 0.74 (10.26 pct ...
05/09/16 06:32 PMBRIEF-Cellular Biomedicine reports Q1 results - Cellular Biomedicine Group Inc says cash and cash equivalents as of march 31, 2016 were $15.7 million compared to $14.9 million as of december 31, 2015 * Cellular biomedicine group reports first quarter 2016 financial results and provides business ...
05/09/16 06:32 PMCellular Biomedicine : Reports First Quarter 2016 Financial Results and Provides Business Highlights - 05/05 CELLULAR BIOMEDICINE GROUP, INC.: Change in Directors or Principal Officers (fo.. 04/20 CELLULAR BIOMEDICINE GROUP, INC.: Unregistered Sale of Equity Securities, Other.. 04/20 CELLULAR BIOMEDICINE: Announces Closing of $43.13 Million Strategic Investment
05/09/16 04:18 PMCellular Biomedicine reports 1Q loss -
05/09/16 03:01 PMCellular Biomedicine Group Reports First Quarter 2016 Financial Results and Provides Business Highlights - [GlobeNewswire] - –Reported Positive Clinical Data from Phase IIb trial of ReJoin ® haMPC therapy– Expanded Stem Cell Platform with the Launch of New Allogeneic Clinical Trial– Closed Strategic Investment of $43.13 million ...
05/05/16 06:58 PMCELLULAR BIOMEDICINE GROUP, INC. : Change in Directors or Principal Officers (form 8-K) - 04/20 CELLULAR BIOMEDICINE GROUP, INC.: Unregistered Sale of Equity Securities, Other.. 04/20 CELLULAR BIOMEDICINE: Announces Closing of $43.13 Million Strategic Investment .. 04/19 Cellular Biomedicine Group Announces Closing of $43.13 Million Strategic ...
05/05/16 11:21 AMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
05/04/16 06:39 PMRSI Alert: Cellular Biomedicine Group (CBMG) Now Oversold - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Cellular Biomedicine Group Inc (CBMG) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $14.7359 per share.
04/20/16 06:56 PMCELLULAR BIOMEDICINE GROUP, INC. : Unregistered Sale of Equity Securities, Other Events (form 8-K) - Item 3.02 Unregistered Sales of Equity Securities. On April 15, 2016, Cellular Biomedicine Group, Inc. (the "Company") completed the second and final closing of a transaction (the "Financing") with Wuhan Dangdai Science & Technology Industries Group Inc ...
04/20/16 04:14 PMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events -
04/19/16 07:13 PMDangdai International Makes $43.1M Strategic Investment in Cellular Biomedicine Group (CBMG) - Cellular Biomedicine Group Inc. (Nasdaq: CBMG) announced the final closing of Wuhan Dangdai Science and Technology Industries Group Inc.’s (“DANGDAI”) $43.13 million aggregate strategic investment for a total of 2,270,000 shares of the Company’s ...
04/19/16 07:30 AMCellular Biomedicine Group Announces Closing of $43.13 Million Strategic Investment from Dangdai International Group Co., Limited, a Wholly-Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc. - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., April 19, 2016-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases ...
03/23/16 02:09 PMETF’s with exposure to Cellular Biomedicine Group, Inc. : March 23, 2016 -
03/21/16 12:16 PMCellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/21/16 09:46 AMCellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: 2015 By the Numbers -
03/14/16 06:00 AMCellular Biomedicine Group Reports Full-Year 2015 Financial Results and Recent Operational Progress - [GlobeNewswire] - -Achieved first clinical milestones for CD19, CD20, CD30 and EGFR CAR-T cell assets- Expanded Immuno-Oncology platform with key acquisitions- Expanded Stem Cell platform with the launch of new autologous ...
03/14/16 05:08 AMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual Report -
02/21/16 09:24 AMCellular Biomedicine Group Inc. (CBMG) - 10-Feb-16 CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events, Financial 28-Jan-16 CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements 12 ...
02/18/16 04:49 PMFundraisings highlight the rise in Chinese pharma R&D - Meanwhile, Cellular Biomedicine Group (CBMG), which has traded on Nasdaq since 2014, provides another way for US investors to place bets on Chinese science. Chi-Med is the most established of the trio, having invested $300m over the past decade and built a ...
02/12/16 09:24 AMDangdai Invests Over US$43 Million In CBMG - Dangdai Science & Technology Industries Group has agreed to invest US$43.13 million in Cellular Biomedicine Group (CBMG). Dangdai will receive 2.27 million shares of CBMG’s common stock, a 19.4 percent stake investment, at US$19 per share. Based in Wuhan ...
02/10/16 04:17 PMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events, Financial -
02/05/16 09:00 AMSCLN Settles FCPA Charges, OGXI On Cost Discipline Mode, Shire To Face FDA - China-based Wuhan Dangdai Science & Technology Industries Group Inc. is all set to take a 19.4% stake in Cellular Biomedicine Group Inc. ( CBMG) by investing $43.13 million in 2.27 million shares of the company, at $19 per share. CBMG closed Thursday's ...
02/05/16 09:00 AMCellular Biomedicine Group (CBMG) Receives $43M Strategic Investment From Dangdai International - Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced Wuhan Dangdai Science ...
02/04/16 03:50 PMCellular Biomedicine's Stock Surges After Company Receives Strategic Investment - Shares of Cellular Biomedicine Group Inc (NASDAQ: CBMG), a biomedical company that is engaged in the development of new treatments for cancerous and degenerative diseases, surged by more than 6 percent on Thursday. Cellular Biomedicine announced it has received a $43.13 million investment from Wuhan Dangdai Science & Technology Industries Group ...Full story available on Benzinga.com
02/04/16 08:56 AMCellular Biomedicine Group Announces a $43.13 Million Strategic - SHANGHAI, China and CUPERTINO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and ...
02/04/16 08:09 AMCellular Biomedicine Group Announces a $43.13 Million Strategic Investment From Dangdai International Group Co., Limited, a Wholly Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc. - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Feb. 04, 2016-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
01/28/16 08:57 PMNew chief at Cellular Biomedicine - Cellular Biomedicine Group (NASDAQ:CBMG) promotes CFO Tony (Bizuo) Liu to Chief Executive Officer effective February 7. He will continue to serve as CFO until a successor is hired. Concurrently, Vice Chairman of the Board Terry Belmont was elected Chairman.
01/28/16 06:54 AMCellular Biomedicine Group Names Tony Liu as CEO - Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced the election of Terry A. Belmont as Chairman of the Board of Directors, and the appointment of Tony (Bizuo) Liu to Chief Executive Officer, effective February 7, 2016. The Board of Directors of CBMG issued the following statement: "We are delighted ...Full story available on Benzinga.com
01/28/16 05:00 AMCellular Biomedicine Group Announces Chairman of the Board of Directors, and Appointment of Chief Executive Officer - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 28, 2016-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
01/11/16 08:00 AMCellular Biomedicine Group Announces CEO Transition - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 11, 2016-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
01/08/16 08:00 AMCellular Biomedicine Group Selected to Present at Biotech Showcase™ 2016 - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 08, 2016-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
01/06/16 08:04 AMCellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 06, 2016-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
12/22/15 08:00 AMCellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Dec. 22, 2015-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
12/08/15 12:18 PMCELLULAR BIOMEDICINE GROUP, INC. Financials -
12/07/15 07:30 AMBeyond the Chart, What Price Data Reveals - Research on XBiotech, Carbonite, Cellular Biomedicine and Hawaiian Telcom - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 7, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: XBiotech Inc. ...
11/30/15 04:26 PMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation -
11/27/15 07:30 AMEquities on the Move - Research on XBiotech, Carbonite, Cellular Biomedicine and Hawaiian Telcom - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 27, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: XBiotech ...
11/24/15 08:08 AMCellular Biomedicine Group to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Nov. 24, 2015-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
11/23/15 08:10 AMCellular Biomedicine Group Announces Voting Results of 2015 Annual General Meeting - [GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Nov. 23, 2015-- Cellular Biomedicine Group Inc., a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies ...
11/16/15 08:38 AMCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Stateme -

Social

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBMG
  • CUSIP:
Key Metrics:
  • Previous Close: $14.80
  • 50 Day Moving Average: $13.96
  • 200 Day Moving Average: $15.86
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $209.77M
  • Beta: 2.69
Additional Links:
Cellular Biomedicine Group (NASDAQ:CBMG) Chart for Saturday, July, 30, 2016